76960-33-3

Basic information

• Product Name: 4-nitro-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzamide
• Synonyms: 4-nitro-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzamide
• CAS NO: 76960-33-3
• Molecular Weight: 256.218
• Mol File: 76960-33-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-nitro-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-nitro-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzamide(76960-33-3)
• EPA Substance Registry System: 4-nitro-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzamide(76960-33-3)

Safety Data

• Hazardous Substances Data: 76960-33-3(Hazardous Substances Data)

Upstream product

• 122-04-3 4-nitro-benzoyl chloride 
• 51-78-5 p-aminophenol hydrochloride 
• 13160-56-0 N-(4-hydroxyphenyl)-4-nitrobenzamide 

Downstream Products

• 1489231-09-5 N-(3-((7H-purin-6-yl)thio)-4-hydroxyphenyl)-4-nitrobenzamide 
• 1489235-56-4 N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)-4-nitrobenzamide 
• 1489235-57-5 N-(4-hydroxy-3-((5-methyl-1,3,4-thiadiazol-2-yl)thio)phenyl)-4-nitrobenzamide 
• 1489231-05-1 N-(3-((1,3,4-thiadiazol-2-yl)thio)-4-hydroxyphenyl)-4-nitrobenzamide 
• 1489231-07-3 N-(4-hydroxy-3-((1-methyl-1H-tetrazol-5-yl)thio)phenyl)-4-nitrobenzamide 
• 76960-35-5 4-{4-(4-nitrobenzoylamino)phenoxy}phenol 

Relevant articles and documents

Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part II

A novel series of 4-amino-2-(thio)phenol derivatives were well synthesized. The preliminary biological test revealed that several compounds displayed high specific protein kinase and angiogenesis inhibitory activities compared with previous work mainly because of the substitution of sulfonamide structure for amide fragment. Among which, compound 5i was identified to inhibit protein kinase B/AKT (IC50 = 1.26 μM) and ABL tyrosine kinase (IC 50 = 1.50 μM) effectively. Meanwhile, compound 5i demonstrated competitive in vitro antiangiogenic activities to Pazopanib in both human umbilical vein endothelial cell (HUVEC) tube formation assay and the rat thoracic aorta rings test.